DYNAVAX TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2009-12-10: Form 8-K; Period of report 2009-12-08; Description 8.01 Other Events; Details 8.01.
- 2009-11-19: Form 8-K; Period of report 2009-11-19; Description 8.01 Other Events; Details 8.01.
- 2009-11-10: Form 8-K; Period of report 2009-11-09; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2009-11-05: Form 8-K; Period of report 2009-11-03; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2009-12-10 | 8-K | 2009-12-08 | 8.01 Other Events | 8.01 On December 8, 2009, Dynavax Technologies Corporation (Dynavax) issued a press release titled "Dynavax's European Manufacturing Facility Approved For Commercial Production of HEPLISAV(TM) Hepatitis B Surface Antigen." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. | rrd259465.htm |
| 2009-11-19 | 8-K | 2009-11-19 | 8.01 Other Events | 8.01 On November 19, 2009, Dynavax Technologies Corporation issued a press release titled "Dynavax Completes Enrollment of First Cohort of Patients in Phase 1b Clinical Trial for Hepatitis B Therapy." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. | rrd257913.htm |
| 2009-11-10 | 8-K | 2009-11-09 | 1.01 Entry into a Material Definitive Agreement | 1.01 On April 18, 2006, Dynavax Technologies Corporation ("Dynavax") entered into a series of related agreements with Symphony Capital Partners, LP ("Symphony"), Symphony Dynamo Holdings LLC ("Holdings") and Symphony Dynamo, Inc. ("SDI"), pursuant to which Holdings formed and capitalized SDI. | rrd256725.htm |
| 2009-11-05 | 8-K | 2009-11-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 3, 2009, the Board of Directors (the "Board") of Dynavax Technologies Corporation ("Dynavax") elected Francis R. Cano, Ph.D. as a Class III director to serve until the 2012 Annual Meeting of Stockholders. | rrd256384.htm |
| 2009-10-29 | 8-K | 2009-10-29 | 8.01 Other Events | 8.01 On October 29, 2009, Dynavax Technologies Corporation (Dynavax) issued a press release titled "Dynavax's HEPLISAV(TM) Shows Increased Protection Rate for Chronic Kidney Disease Patients." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. | rrd255870.htm |
| 2009-10-23 | 8-K | 2009-10-22 | 2.02 Results of Operations and Financial Condition | 2.02 On October 22, 2009, Dynavax Technologies Corporation ("Dynavax"), issued a press release announcing its financial results for third quarter ended September 30, 2009. | rrd255466.htm |
| 2009-09-29 | 8-K | 2009-09-29 | 8.01 Other Events | 8.01 On September 29, 2009, Dynavax Technologies Corporation (Dynavax) issued a press release titled "Dynavax Initiates Phase 3 Registration Trial in Chronic Kidney Disease Patients for HEPLISAV(TM) Hepatitis B Vaccine." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. | rrd253914.htm |
| 2009-09-11 | 8-K | 2009-09-10 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On September 10, 2009, Dynavax Technologies Corporation (“Dynavax”) amended its engagement letter, with Wedbush Morgan Securities, Inc. (“Wedbush”), dated August 10, 2009, and its equity distribution agreement with Wedbush, dated August 17, 2009, to remove provisions requiring that Dynavax pay Wedbush in the event Dynavax entered into or announced an at-the-market offering with a sales agent other than Wedbush within a period of three months following termination of the engagement. 8.01 On September 10, 2009, Dynavax Technologies Corporation (Dynavax) issued a press release titled “Dynavax Reports FDA Removes Clinical Hold On HEPLISAVTM Phase 3 Hepatitis B Vaccine.” A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. | d8k.htm |
| 2009-08-20 | 8-K | 2009-08-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 7, 2009, Dynavax Technologies Corporation ("Dynavax" or the "Company") announced the promotion of Jennifer Lew to Vice President, Finance. | rrd251263.htm |
| 2009-08-17 | 8-K | 2009-08-17 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d8k.htm |
| 2009-08-12 | 8-K | 2009-08-12 | 8.01 Other Events | 8.01 On August 12, 2009, Dynavax Technologies Corporation (Dynavax) issued a press release titled "Dynavax Announces European Development Strategy for HEPLISAV(TM) Hepatitis B Vaccine." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. | rrd250486.htm |
| 2009-08-07 | 8-K | 2009-08-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 7, 2009, Dynavax Technologies Corporation ("Dynavax" or the "Company") announced that Deborah A. Smeltzer, Vice President, Operations and Chief Financial Officer, is planning to retire by year-end. | rrd250211.htm |
| 2009-08-05 | 8-K | 2009-08-04 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On August 4, 2009, Dynavax Technologies Corporation ("Dynavax"), issued a press release announcing its financial results for second quarter ended June 30, 2009. | rrd249887.htm |
| 2009-06-10 | 8-K | 2009-06-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 5, 2009, Dynavax Technologies Corporation ("Dynavax" or the "Company") appointed Jennifer Lew as Principal Accounting Officer. | rrd245542.htm |
| 2009-06-05 | 8-K | 2009-06-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 4, 2009, Dynavax Technologies Corporation ("Dynavax" or the "Company") amended the current Management Continuity Agreement (the "Agreement") with Zbigniew Janowicz, Ph.D., its Chief Executive Officer and Managing Director of Rhein Biotech GmbH (Dynavax Europe), in order to: (a) address the requirements of certain Section 409(a) U.S. tax regulations; (b) amend existing option grants to extend the exercise period for vested options in the event of a change of control; and (c) conform certain of the terms of the Agreement for consistency with Dr. Janowicz's existing employment agreement and applicable German Law. | rrd245177.htm |
| 2009-06-03 | 8-K | 2009-06-03 | 8.01 Other Events | 8.01 On June 3, 2009, Dynavax Technologies Corporation (Dynavax) issued a press release titled "Dynavax Presents Additional Phase 3 Data for HEPLISAV(TM) Hepatitis B Vaccine at DDW Medical Conference." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. | rrd244871.htm |
| 2009-04-30 | 8-K | 2009-04-30 | 8.01 Other Events | 8.01 On April 30, 2009, Dynavax Technologies Corporation (Dynavax) issued a press release titled "Dynavax Presents Data from Novel Universal Flu Vaccine Candidate." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. | rrd240968.htm |
| 2009-04-29 | 8-K | 2009-04-28 | 2.02 Results of Operations and Financial Condition | 2.02 On April 28, 2009, Dynavax Technologies Corporation issued a press release announcing its financial results for first quarter ended March 31, 2009. | rrd240831.htm |
| 2009-04-28 | 8-K | 2009-04-27 | 8.01 Other Events | 8.01 On April 27, 2009, Dynavax Technologies Corporation (Dynavax) issued a press release titled "Dynavax Presents Additional Phase 3 Data for HEPLISAV(TM) Hepatitis B Vaccine at EASL Medical Conference." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. | rrd240591.htm |
| 2009-03-13 | 8-K | 2009-03-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 10, 2009, our Board of Directors approved stock option awards for each of Dynavax's named executive officers and delegated authority to the Chief Executive Officer to determine and approve the stock option award for the Chief Executive Officer of Dynavax Europe. | rrd237238.htm |
| 2009-03-02 | 8-K | 2009-03-02 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On March 2, 2009, Dynavax Technologies Corporation (Dynavax) issued a press release announcing its financial results for fourth quarter and year ended December 31, 2008, and provided its 2009 financial outlook. 8.01 Phase 3 HEPLISAVTM hepatitis B vaccine - Dynavax is seeking clarification of the remaining regulatory requirements for development and licensure of HEPLISAV in the United States and Europe and expects to have sufficient information in the first half of 2009 to determine a path forward, if any. | rrd235823.htm |
| 2009-02-09 | 8-K | 2009-02-05 | 8.01 Other Events | rrd232477.htm | |
| 2009-02-02 | 8-K | 2009-01-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 27, 2009, the Compensation Committee of our Board of Directors, or Board, determined and approved the 2008 bonus and 2009 base salary for each of Dynavax's named executive officers other than our President and Chief Executive Officer, or CEO, and the Chief Executive Officer of Dynavax Europe. | rrd231502.htm |